Metropolis Healthcare Limited has informed the Exchange regarding 'Business update for Q3FY26'
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare reported a strong 26% year-on-year consolidated revenue growth for Q3FY26, driven by its TruHealth wellness and specialty testing segments. The TruHealth wellness segment grew ~35% YoY and the specialty segment grew ~33% YoY. B2C revenues rose ~18% and B2B revenues jumped ~37%, helped by higher specialty test volumes and a bigger share of B2B business in Core Diagnostics. On a standalone basis, revenue grew ~15% YoY with EBITDA margins expanding despite Q3 being a seasonally weaker quarter for diagnostics. Recently acquired businesses — Scientific Pathology (Agra), DAPIC (Dehradun), and Ambika Pathology (Kolhapur) — are outperforming the company's average margins, and Core Diagnostics margins are holding steady at Q2 levels.
Positive read for shareholders — broad-based, above-industry growth across both segments and channels, combined with margin expansion and strong contribution from acquisitions, points to a healthy earnings print when detailed Q3 results are announced.